Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
  • Every Breakthrough
    Begins With You

    Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

    Learn more about Only Possible Here
    Donate Today only-possible-here-logo
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • STRIDE
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      Haniel Araujo Image

      Haniel Araujo, MD

      Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine

      Present Title & Affiliation

      Primary Appointment

      Assistant Professor, Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Education & Training

      Degree-Granting Education

      2015University of São Paulo Medical School, Sao Paulo, BR, Medicine

      Postgraduate Training

      2022-2024Clinical Fellow, University of Texas MD Anderson Cancer Center, Houston, Texas
      2019-2022Clinical Fellow, University of Sao Paulo Medical School, Sao Palo
      2016-2018Resident, University of Sao Paulo Medical School, Sao Paulo

      Licenses & Certifications

      2024Texas Medical License
      2018ECFMG certification

      Experience & Service

      Other Professional Positions

      KRAS-mutant NSCLC working group, University of Texas MD Anderson Cancer Center, 2024 - Present

      The Oncogene-driven NSCLC working group, University of Texas MD Anderson Cancer Center, 2024 - Present

      Editorial Activities

      Journal Reviewer, Journal of Clinical Investigation, 2025 - Present

      Journal Reviewer, Journal of Experimental & Clinical Cancer Research, 2024 - Present

      Honors & Awards

      2023Endowed Fellowship Research Award, The University of Texas MD Anderson Cancer Center
      2015Award for being the medical student with higher grades graduated in the 2015 class, University of Sao Paulo Medical School, Brazil
      2013“Fundação Faculdade de Medicina” award – Best Medical Student`s Research Project, University of São Paulo Medical School, Brazil

      Professional Memberships

      European Society of Medical Oncology (ESMO)

      2024 - Present

      American Society of Clinical Oncology (ASCO)

      2023 - Present

      American Association for Cancer Research (AACR)

      2023 - Present

      Selected Presentations & Talks

      Local Presentations

      1. 2025. Clinico-genomic predictors of Immunotherapy response in KRAS mutant NSCLC. Invited. Revolution Medicines Clinical Immersion in the Management of Non-Small Cell Lung Cancer (NSCLC). Houston, Texas, US.

      National Presentations

      1. 2023. Molecular determinants of KRAS p.G12C inhibitor efficacy in advanced NSCLC. Orlando, Florida, US.
      2. 2021. Proton pump inhibitors and antibiotics impact on toxicities and clinical outcomes in cancer patients treated with immunotherapy, US.

      International Presentations

      1. 2025. Dissecting response and tolerance to RAS inhibitors in NSCLC. Invited. The 84th Annual Meeting of the Japanese Cancer Association International Cancer Meeting in Kanazawa. Kanazawa City, JP.
      2. 2025. Zoldonrasib, a RAS(ON) G12D-Selective, Inhibitor in patients with KRAS G12D mutated NSCLC. Invited. Kona, US.
      Read More
      Less

      Grant & Contract Support

      Date: 2026 - 2031
      Title:Elucidating roles of the CD24 ligand in early lung cancer development, immune evasion and response to KRAS-targeted therapy
      Funding Source:NIH/NCI
      Role:Co-I
      ID:Project Number: FP00027263
      Date: 2025 - 2030
      Title:Elucidating roles of the CD24 ligand in early lung cancer development, immune evasion and response to KRAS-targeted therapy
      Funding Source:NIH
      Role:Co-I
      ID:Project Number: FP00023340_Res1
      Date: 2025 - 2027
      Title:Molecular determinants of efficacy of KRASG12C Inhibitor Efficacy in Advanced NSCLC. Early-Career Clinical and Translational Research
      Funding Source:UT MD Anderson Cancer Center
      Role:PI
      Date: 2025 - Present
      Title:Spatial transcriptomic and immune contexture determinants of response and persistence to KRAS G12C inhibition in KRAS -mutant NSCLC
      Funding Source:Andrew Sabin Family Foundation Award,
      Role:PI
      Date: 2025 - Present
      Title:Targeting MUC1 to overcome tolerance to RAS inhibition in NSCLC
      Funding Source:Lungevity
      Role:PI
      Date: 2022 - 2025
      Title:Evaluating the antitumor efficacy of RAS (ON) inhibitors in immune competent models of KRAS-mutant NSCLC
      Funding Source:Revolution Medicines
      Role:Co-I
      ID:Project Number: 00014800

      Selected Publications

      Peer-Reviewed Articles

      1. Li, H, Salehjahromi, M, Godoy, M, Qin, K, Plummer, CM, Zhang, Z, Hong, L, Heeke, S, Le, X, Vokes, N, Zhang, B, Araujo, HA, Altan, M, Wu, CC, Antonoff, MB, Ostrin, EJ, Gibbons, DL, Heymach, JV, Lee, JJ, Gerber, DE, Wu, J, Zhang, J. Lung Cancer Risk Prediction in Patients with Persistent Pulmonary Nodules Using the Brock Model and Sybil Model. Cancers 17(9), 2025. e-Pub 2025. PMID: 40361426.
      2. Araujo HA, Pechuan-Jorge X, Zhou T, Do MT, Hu X, Rojas Alvarez FR, Salvatierra ME, Ibarguen HP, Lee R, Raghulan R, Shah H, Moreno Ayala MA, Chen K, Tovbis Shifrin N, Wu S, Solis Soto LM, Negrao MV, Gibbons DL, Hong DS, Roth JA, Heymach JV, Zhang J, Jiang J, Singh M, Smith JAM, Quintana E, Skoulidis F. Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non-Small Cell Lung Cancer. Cancer Discov 14(11):2183-2208, 2024. e-Pub 2024. PMID: 38975897.
      3. Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Galan-Cobo A, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbo F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Leighl NB, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Janne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature 635(8038):462-471, 2024. e-Pub 2024. PMID: 39385035.
      4. Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discov 13(7):1556-1571, 2023. e-Pub 2023. PMID: 37068173.
      5. Tanaka LY, Araujo HA, Hironaka GK, Araujo TL, Takimura CK, Rodriguez AI, Casagrande AS, Gutierrez PS, Lemos-Neto PA, Laurindo FR. Peri/Epicellular Protein Disulfide Isomerase Sustains Vascular Lumen Caliber Through an Anticonstrictive Remodeling Effect. Hypertension 67(3):613-22, 2016. e-Pub 2016. PMID: 26781284.
      6. Quillard T, Araujo HA, Franck G, Shvartz E, Sukhova G, Libby P. TLR2 and neutrophils potentiate endothelial stress, apoptosis and detachment: implications for superficial erosion. Eur Heart J 36(22):1394-404, 2015. e-Pub 2015. PMID: 25755115.
      7. Quillard T, Araujo HA, Franck G, Tesmenitsky Y, Libby P. Matrix metalloproteinase-13 predominates over matrix metalloproteinase-8 as the functional interstitial collagenase in mouse atheromata. Arterioscler Thromb Vasc Biol 34(6):1179-86, 2014. e-Pub 2014. PMID: 24723558.

      Other Articles

      1. Skoulidis, F, Araujo, HA, Do, MT, Qian, Y, Sun, X, Cobo, AG, Le, JT, Montesion, M, Palmer, R, Jahchan, NS, Juan, J, Min, C, Yu, Y, Pan, X, Arbour, KC, Vokes, N, Schmidt, S, Molkentine, D, Owen, D, Memmott, R, Patil, P, Marmarelis, ME, Awad, MM, Murray, J, Hellyer, JA, Gainor, J, Dimou, A, Bestvina, CM, Shu, CA, Riess, JW, Blakely, CM, Pecot, CV, Mezquita, L, Tabbò, F, Scheffler, M, Digumarthy, S, Mooradian, MJ, Sacher, A, Lau, SC, Saltos, A, Rotow, JK, Johnson, RP, Liu, C, Stewart, TF, Goldberg, SB, Killam, J, Walther, Z, Schalper, K, Davies, KD, Woodcock, MG, Anagnostou, V, Marrone, KA, Forde, PM, Ricciuti, B, Venkatraman, D, Van Allen, EM, Cummings, AL, Goldman, JW, Shaish, H, Kier, M, Katz, S, Aggarwal, C, Ni, Y, Azok, J, Segal, J, Ritterhouse, LL, Neal, JW, Lacroix, L, Elamin, YY, Vailati Negrao, M, Le, X, Lam, VK, Lewis, WE, Kemp, HN, Carter, B, Roth, JA, Swisher, S, Lee, R, Zhou, T, Poteete, A, Kong, Y, Takehara, T, Paula, AG, Parra Cuentas, ER, Behrens, MC, Wistuba, II, Zhang, J, Blumenschein, GR, Gay, CM, Byers, LA, Gibbons, DL, Tsao, A, Lee, JJ, Bivona, T, Camidge, DR, Gray, JE, Leighl, NB, Levy, BP, Brahmer, JR, Garassino, MC, Gandara, D, Garon, EB, Rizvi, NA, Scagliotti, G, Wolf, J, Planchard, D, Besse, B, Herbst, RS, Wakelee, HA, Pennell, N, Shaw, AT, Jänne, PA, Carbone, DP, Hellmann, MD, Rudin, CM, Albacker, LA, Mann, H, Zhu, Z, Lai, Z, Stewart, RA, Peters, S, Johnson, M, Wong, KK, Huang, A, Winslow, MM, Rosen, MJ, Winters, IP, Papadimitrakopoulou, VA, Cascone, T, Jewsbury, P, Heymach, JV Correction to. Nature 639(8054):E19, 2025. PMID: 40016449.

      Abstracts

      1. Araujo HA, Venchiarutti Moniz CM, Melro Braghiroli OF, Mak MP, Uratani LF, Tiecher RD, Moraes PM, Barbosa I, De Camargo VP, Melro Braghiroli MIF, Jr GC, Hoff PM, Pilar Diz MD. Proton pump inhibitors and antibiotics impact on toxicities and clinical outcomes in cancer patients treated with immunotherapy. American Society of Clinical Oncology (ASCO).
      2. Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Zhou T, Akhave N, Delasos L, Hicks J, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott S, Bironzo P, Scheffler M, Christopoulos P, Kim SY, Goldberg S, Ni Y, Resuli B, Landi L, Tseng S, Nishino M, Owen D, Blakely C, Mountzios G, Shu CA, Bestvina C, Garassino M, Marrone K, Gray J, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil P, Gibbons DL, Meric-Bernstam F, Lee J, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. Molecular determinants of KRAS p.G12C inhibitor efficacy in advanced NSCLC. American Association for Cancer Research Annual Meeting (AACR).
      3. Rahal Z, Yang S, Chen M, Reischle IT, Zhou T, Zhou T, Gomez Bolanos LI, Serrano AG, Sinjab A, Feng J, Solis Soto LM, Wistuba II, Araujo HA, Skoulidis F, Kadara H. CD24 promotes development of KRAS-mutant lung adenocarcinoma and response to KRAS-targeted therapy. American Association for Cancer Research (AACR).
      4. King N, Hong L, Rinsurongkawong W, Young E, Sui D, McNeill L, Rinsurongkawong V, Lewis J, Lee J, Altan M, Zhang B, Vokes N, Le X, Tran H, Araujo H, Gibbons D, Vaporciyan A, Heymach J, Zhang J, Lin J. Race-associated clinicogenomic correlates of outcomes to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer (NSCLC). American Society of Clinical Oncology (ASCO).

      Book Chapters

      1. Araujo H, Skoulidis F. Treatment of advanced KRAS-mutated NSCLC. In: Thoracic Tumors Essentials for Clinicians - Chapter 11.
      2. Araujo H, Singhi EK, Elamin YY, Negrao MV. Targeted therapies in non-small cell lung cancer. In: MD Anderson Manual of Medical Oncology. Fifth.
      Read More
      Less

      Patient Reviews


      CV information above last modified July 22, 2026

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Care Centers and Clinics

      • Departments and Divisions

      • Labs

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top